EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma

Chelsea Kotch, Alicia Gomes, Krista S Schatz, Eva Dombi, Symone Brown, Andrea M Gross, Mélanie Alves, Sébastien Perreault, Sabine Mueller, Alyssa T Reddy, Carlos Romo, Miriam Bornhorst und 4 weitere

Human Genetics · 2025

DOI: 10.1007/s00439-025-02786-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Human Genetics, 2025. Verfasst von Chelsea Kotch und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Children's Hospital of Philadelphia, 3500 Civic Center Blvd, Philadelphia, PA, 19104, USA. kotchc@chop.edu. Hauptthemen laut MEDLINE: Neurofibromin 1, Neurofibroma, Plexiform, Germ-Line Mutation, Genetic Predisposition to Disease. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Neurofibromatosis Therapeutic Acceleration Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with neurofibromatosis type 1 (NF1) enrolled on interventional clinical trials of a mitogen activated protein kinase (MEK) inhibitor for a plexiform neurofibroma (PN) are required to have inoperable, progressive and/or symptomatic tumor as per protocol inclusion criteria. Thus, the represented germline pathogenic NF1 variants of these clinical trial participants may correlate with increased risk for symptomatic and/or progressive PN. However, the spectrum of pathogenic NF1 variants of participants enrolled on interventional clinical trials has not been previously described. Herein, we report 39 individuals with a diagnosis of NF1 per the National Institutes of Health consensus criteria who received treatment with a MEK inhibitor through a clinical trial for a morbid and/or progressive PN. Truncating variants were the most common variant (N = 14; 36.8%), followed by frameshift (N = 10; 26.3%) and canonical splice/intronic (N = 7; 18.4%); only 1 participant had a NF1 microdeletion (2.5%). Three variants were noted to be recurrent in the study population (c.6789_6792del (p.Tyr2264Thrfs*5), c.4537 C > T (p.Arg1513*), and c.3826 C > T (p.Arg1276*)); there were no related study participants. There was no significant difference in rates of PN response to MEK inhibition across NF1 variant subtype (P = 0.616). In summary, the reported NF1 germline variants may represent those associated with an increased likelihood of symptomatic PN, however sample size limits inference regarding correlation. Contribution of this study’s findings to the literature may support future development of more accurate risk stratification for PN in individuals with NF1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromin 1Neurofibroma, PlexiformGerm-Line MutationGenetic Predisposition to DiseaseProtein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein Kinase KinasesHumansMaleFemaleCohort StudiesChildInfantChild, PreschoolAdolescentYoung AdultGenetic Association Studies

Substanzen

Neurofibromin 1Protein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Division of Oncology, Children's Hospital of Philadelphia, 3500 Civic Center Blvd, Philadelphia, PA, 19104, USA. kotchc@chop.edu.
  • University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. kotchc@chop.edu.
  • Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
  • Division of Oncology, Children's Hospital of Philadelphia, 3500 Civic Center Blvd, Philadelphia, PA, 19104, USA.

Förderung

  • NCI NIH HHS
  • Neurofibromatosis Therapeutic Acceleration Program

Zitieren

APA

Kotch, C., Gomes, A., Schatz, K. S., Dombi, E., Brown, S., Gross, A. M., Alves, M., Perreault, S., Mueller, S., Reddy, A. T., Romo, C., Bornhorst, M., Tonsgard, J., Weiss, B. D., Widemann, B., & Fisher, M. J. (2025). The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma. Human Genetics. https://doi.org/10.1007/s00439-025-02786-2

Vancouver

Kotch C, Gomes A, Schatz KS, Dombi E, Brown S, Gross AM, et al. The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma. Human Genetics. 2025. doi:10.1007/s00439-025-02786-2

BibTeX
@article{Kotch2025,
  author = {Kotch, Chelsea and Gomes, Alicia and Schatz, Krista S and Dombi, Eva and Brown, Symone and Gross, Andrea M and Alves, Mélanie and Perreault, Sébastien and Mueller, Sabine and Reddy, Alyssa T and Romo, Carlos and Bornhorst, Miriam and Tonsgard, James and Weiss, Brian D and Widemann, Brigitte and Fisher, Michael J},
  title = {The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma},
  journal = {Human Genetics},
  year = {2025},
  doi = {10.1007/s00439-025-02786-2}
}
Kostenlos starten →